Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
高シグナルの見出しのみ — マクロイベント、決算、M&A、規制。リスト記事とアナリストのクリックベイトはデフォルトでフィルタ。1時間ごとに更新。
Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.
Gregory Demopulos: Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer; Dr. Cathy Melfi, our Chief Regulatory Officer; and Dr. Steve Whitaker, Vice President of Clinical. After that, David will cover the financials in more detail and then we'll open the call for questions.
Moby summary of Omeros Corporation's Q1 2026 earnings call
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive
Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi
Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.
The telehealth platform posted a quarterly loss of $92.1 million, driven by higher expenses, including those tied to operations, technology and general and administrative functions.
Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter 2026 earnings call on May 7. Chief Executive Officer Mike Exton said the company entered 2026 with o
Find insight on Amazon Pharmacy, Sanofi, Sunway Health and more in the latest Market Talks covering the health care sector.
LONDON/COPENHAGEN, May 7 (Reuters) - Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the market to millions more patients and help counter pricing pressure. Denmark's Novo, which has struggled to keep pace with U.
While investors obsess over uptake of GLP-1 pills in the U.S., international sales are just as important.
Find insight on Novo Nordisk, Hartalega, Smith & Nephew and more in the latest Market Talks covering Health Care.
Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.
May 6 (Reuters) - European shares rose on Tuesday, with oil prices dropping and investor optimism rising after U.S.
ON Semiconductor, Pfizer, Uber, McDonald’s, and many more will report earnings this week. Economic releases will include the April jobs report and purchasing managers index.